Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Impact
The establishment of the Cancer Research Fund within the Department of the Treasury marks a critical shift in how cancer research is funded in New Jersey. By ensuring that at least $5 million is explicitly earmarked for pediatric cancer research and another $5 million for general cancer research, the bill directly addresses both the breadth and depth of cancer issues affecting various populations. It aims to enhance access to high-quality cancer care and research for minority and vulnerable communities in the state. This approach is likely to increase participation in clinical trials and research funding focused on reducing health disparities related to cancer.
Summary
Assembly Bill A4677 proposes to increase the annual allocation of cigarette and other tobacco products tax revenues to the New Jersey Commission on Cancer Research (NJCCR) from $1 million to $10 million. This significant increase aims to provide essential funding for various cancer research initiatives, allowing for a more robust approach to studying cancer causes, prevention, treatment, and care. The bill establishes a dedicated, non-lapsing Cancer Research Fund, ensuring that these resources are not subject to the annual appropriations act, which historically has redirected available funds away from the NJCCR to the General Fund for other uses.
Contention
Despite the benefits outlined in the bill, there could be contention regarding the use of tobacco tax revenues. Some stakeholders may argue against allocating these funds for cancer research rather than utilizing them for preventive health programs or cessation initiatives. Additionally, while the NJCCR has historically received limited funding, recent appropriations controversies may provoke debates about ensuring sustainable funding channels and accountability for cancer research expenditures. Opponents might question the efficiency of funneling more tax revenue into a system perceived as bureaucratic or poorly managed, calling for a transparent framework on fund allocation and outcomes.
Same As
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Carry Over
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Carry Over
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research from $1 million to $4 million; establishes dedicated, non-lapsing Cancer Research Fund.